Supernus Pharmaceuticals (SUPN)

Executive Summary

Supernus Pharmaceuticals is a publicly traded biopharmaceutical company focused on CNS disorders, with a portfolio of eight marketed products and a pipeline including NV-5138 (Phase 2 for major depressive disorder) and SPN-817 (Phase 2 for focal seizures). The company's proprietary drug delivery technologies underpin its commercial success, generating stable revenue from products like Trokendi XR and Oxtellar XR. With a strong balance sheet and ongoing R&D, Supernus aims to address unmet needs in neurology and psychiatry. Key near-term milestones include the disclosure of NV-5138 Phase 2 top-line data, which could validate its novel mechanism and drive share appreciation. However, pipeline risks remain, as SPN-817 is still enrolling and other candidates are early-stage. Overall, Supernus offers a balanced risk-reward profile with a solid commercial base and selective pipeline upside.

Upcoming Catalysts (preview)

• Q3 2026NV-5138 Phase 2 topline results for major depressive disorder60% success
• H1 2027SPN-817 Phase 2 enrollment completion and interim data for focal seizures50% success
• TBDPotential label expansion or new product approval in CNS40% success